{"id":140877,"date":"2025-10-07T18:39:24","date_gmt":"2025-10-07T22:39:24","guid":{"rendered":"https:\/\/medcitynews.com\/?p=140877"},"modified":"2025-10-09T22:52:33","modified_gmt":"2025-10-10T02:52:33","slug":"boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/","title":{"rendered":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF"},"content":{"rendered":"<p>Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the opportunity to bring a different approach to the fatal disease with the first <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-treat-idiopathic-pulmonary-fibrosis\" target=\"_blank\" rel=\"noopener\">new FDA-approved IPF therapy<\/a> in more than a decade.<\/p>\n<p>The FDA\u2019s Tuesday regulatory decision for the drug, nerandomilast, covers the treatment of IPF in adults. Germany-based Boehringer, which maintains its U.S. headquarters in Ridgefield, Connecticut, will market the twice-daily pill under the brand name Jascayd.<\/p>\n<p>In IPF, lung tissue becomes thick and stiff. As this tissue leads to permanent scarring called fibrosis, patients find it harder and harder to breath. Shortness of breath and chronic cough are common symptoms. Many IPF patients also experience acute exacerbations, periods when symptoms suddenly intensify. The exact cause of IPF is not known.<\/p>\n<p>The standard of care for IPF includes two older drugs, nintedanib and pirfenidone. Both are oral small molecules, each one designed to block a different protein involved in the formation of fibrotic tissue. The FDA approved the two drugs in 2014. Nintedanib, <a href=\"https:\/\/www.prnewswire.com\/news-releases\/ofev-nintedanib-now-available-in-the-united-states-729450142.html\" target=\"_blank\" rel=\"noopener\">brand name Ofev<\/a>, is the product from Boehringer. The privately held company reported <a href=\"https:\/\/www.boehringer-ingelheim.com\/us\/about-us\/who-we-are\/2024-results-research-and-development-investment-rise\" target=\"_blank\" rel=\"noopener\">\u20ac3.8 billion<\/a> (about $4 billion) in Ofev revenue last year.\u00a0Neither Ofev nor pirfenidone cures IPF but they can slow its progression.<\/p>\n<p>Jascayd is also not a cure, but it slows IPF progression with a different mechanism of action. This drug, an oral small molecule formulated as a twice-daily pill, is designed to block phosphodiesterase 4B (PDE4B), an enzyme that plays a role in regulating inflammation. Boehringer evaluated Jascayd in two placebo-controlled Phase 3 studies.<\/p>\n<p>The main goal of the studies was measuring the change in forced vital capacity (FVC), how much air a person can exhale after taking a deep breath. Results of the 52-week study showed that patients treated with the study drug had a significantly smaller decline in FVC from baseline compared to those given a placebo. The most common side effects reported in the trial included diarrhea, Covid-19 infection, upper respiratory tract infection, depression, weight loss, and decreased appetite. The Phase 3 results were <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2414108\" target=\"_blank\" rel=\"noopener\">published<\/a> in May in the New England Journal of Medicine.<\/p>\n<p>Financial analysts that cover companies developing IPF drugs expected FDA approval for Jascayd given its Phase 3 results. But Leerink Partners\u2019 Faisal Khurshid said in a September note to investors that the Boehringer drug\u2019s contribution to the field is incremental due to \u201cmodest efficacy and a complicated story.\u201d Use of the drug on top of existing anti-fibrotic drugs leads to complications \u2014 drug-drug interactions with pirfenidone and overlapping diarrhea with Ofev.<\/p>\n<p>\u201cA new therapy for this high unmet need population should nonetheless be accepted by physicians and patients,\u201d Khurshid said.<\/p>\n<p>IPF research has had some notable setbacks. Pliant Therapeutics, which at one time was considered a frontrunner with bexotegrast, <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/07\/3129637\/0\/en\/Pliant-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2025-Financial-Results.html\" target=\"_blank\" rel=\"noopener\">discontinued development<\/a> of the molecule earlier this year after <a href=\"https:\/\/medcitynews.com\/2025\/02\/pliant-therapeutics-bexotegrast-ipf-idiopathic-pulmonary-fibrosis-respiratory-plrx\/\" target=\"_blank\" rel=\"noopener\">Phase 2b\/3 data showed an unfavorable risk\/benefit profile<\/a>.<\/p>\n<p>Other companies remain in the chase, some with new takes on older drugs. Celea Therapeutics spun out of PureTech Health in August with deupirfenidone (formerly LYT-100), a version of pirfenidone with modifications to reduce the adverse effects that limit patient uptake. This oral drug is entering Phase 3 testing. Avalyn Pharma recently <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/22\/3119277\/0\/en\/Avalyn-Completes-Oversubscribed-100-Million-Series-D-Financing-to-Further-Advance-Clinical-Development-of-Novel-Inhaled-Therapies-for-Pulmonary-Fibrosis.html\" target=\"_blank\" rel=\"noopener\">raised $100 million<\/a> for mid-stage testing of its candidates, inhaled versions of pirfenidone and nintedanib intended to offer improved tolerability over the original oral medicines. Last month, United Therapeutics reported that Tyvaso, an inhaled therapy first approved to treat pulmonary arterial hypertension, <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250902497962\/en\/United-Therapeutics-Corporation-Announces-TETON-2-Pivotal-Study-of-Tyvaso-Meets-Primary-Endpoint-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis\" target=\"_blank\" rel=\"noopener\">met the main goal of a Phase 3 test in IPF<\/a>.<\/p>\n<p>Novel IPF medicines are also in development. Insilico Medicine is conducting a U.S. Phase 2 study evaluating a <a href=\"https:\/\/medcitynews.com\/2024\/09\/ai-designed-drug-insilico-medicine-ipf-idiopathic-pulmonary-fibrosis-clinical-trial\/\" target=\"_blank\" rel=\"noopener\">TNIK inhibitor discovered by the company\u2019s proprietary artificial intelligence technologies<\/a>. Contineum Therapeutics is proceeding to Phase 2 testing with <a href=\"https:\/\/medcitynews.com\/2024\/04\/jj-partnered-contineum-corrals-110m-from-ipo-for-clinical-trials-in-fibrosis-ms\/\" target=\"_blank\" rel=\"noopener\">PIPE-791, a once-daily oral small molecule inhibitor of LPA1<\/a>, a receptor that contributes to fibrosis.<\/p>\n<p><em>Photo: Kettel\/ullstein bild, via Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim\u2019s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn\u2019t cure IPF but clinical trial results showed it slowed disease progression. <\/p>\n","protected":false},"author":25932,"featured_media":139185,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,123,54],"tags":[2451,12102,6207,16902,7110],"class_list":["post-140877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-legal","category-pharma-channel","tag-boehringer-ingelheim","tag-clinical-trials","tag-fda","tag-idiopathic-pulmonary-fibrosis","tag-lung-disease"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim\u2019s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn\u2019t cure IPF but clinical trial results showed it slowed disease progression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T22:39:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T02:52:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF\",\"datePublished\":\"2025-10-07T22:39:24+00:00\",\"dateModified\":\"2025-10-10T02:52:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\"},\"wordCount\":662,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg\",\"keywords\":[\"Boehringer Ingelheim\",\"Clinical Trials\",\"FDA\",\"idiopathic pulmonary fibrosis\",\"lung disease\"],\"articleSection\":[\"BioPharma\",\"Legal\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\",\"url\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\",\"name\":\"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg\",\"datePublished\":\"2025-10-07T22:39:24+00:00\",\"dateModified\":\"2025-10-10T02:52:33+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg\",\"width\":1024,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News","og_description":"Boehringer Ingelheim\u2019s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn\u2019t cure IPF but clinical trial results showed it slowed disease progression.","og_url":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/","og_site_name":"MedCity News","article_published_time":"2025-10-07T22:39:24+00:00","article_modified_time":"2025-10-10T02:52:33+00:00","og_image":[{"width":1024,"height":675,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF","datePublished":"2025-10-07T22:39:24+00:00","dateModified":"2025-10-10T02:52:33+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/"},"wordCount":662,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg","keywords":["Boehringer Ingelheim","Clinical Trials","FDA","idiopathic pulmonary fibrosis","lung disease"],"articleSection":["BioPharma","Legal","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/","url":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/","name":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg","datePublished":"2025-10-07T22:39:24+00:00","dateModified":"2025-10-10T02:52:33+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/08\/Boehringer_Ingelheim.jpg","width":1024,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2025\/10\/boehringer-ingelheim-ipf-fda-approval-idiopathic-pulmonary-fibrosis-nerandomilast-jascayd-pde4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/140877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=140877"}],"version-history":[{"count":0,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/140877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/139185"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=140877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=140877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=140877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}